3-((tert-butoxycarbonyl)amino)butyl 4-methylbenzenesulfonate | 135065-66-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-((tert-butoxycarbonyl)amino)butyl 4-methylbenzenesulfonate
• 英文别名: 3-(N-(BOC)amino)butyl 4-methylbenzene sulfonate；3-(t-butoxycarbonylamino)butyl p-toluenesulphonate；3-[(2-Methylpropan-2-yl)oxycarbonylamino]butyl 4-methylbenzenesulfonate
• CAS: 135065-66-6
• 化学式: C₁₆H₂₅NO₅S
• 分子量: 343.444
• InChiKey: LSFHVLXNGGTOBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  90.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-羟基-3,4,8-三甲基香豆素 、 3-((tert-butoxycarbonyl)amino)butyl 4-methylbenzenesulfonate 在 potassium carbonate 作用下， 以 N-甲基乙酰胺 、 水 、 乙酸乙酯 为溶剂， 生成 7-[(RS)-3-(t-butoxycarbonylamino)butoxy]-3,4,8-trimethylcoumarin
  参考文献：
  名称：

  Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders

  摘要：

  公开号：

  EP0411912B1

文献信息

• [EN] DERIVATIVES OF SUBSTITUTED FUSED RING CYCLOINDOLES AND METHODS OF THEIR USE<br/>[FR] DÉRIVÉS DE CYCLOINDOLES À CYCLE CONDENSÉ SUBSTITUÉ ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ITHERX PHARMACEUTICALS INC

  公开号：WO2009103022A1

  公开（公告）日：2009-08-20

  Disclosed herein are derivatives of substituted fused ring cycloindole useful, inter alia, in combating Hepatitis C infection and entry into cells.

  本文披露了替代融合环环己吲哚衍生物，可用于抑制丙型肝炎感染并阻止进入细胞。
• Substituted pyridine compounds useful for controlling chemical synaptic transmission
  申请人：——

  公开号：US20010034357A1

  公开（公告）日：2001-10-25

  The present invention is directed to a series of substituted pyridine compounds, a method for selectively controlling neurotransmitter release in mammals using these compounds, and pharmaceutical compositions containing these compounds. Preferred compounds are 3′-(5′- and/or 6′-substituted) pyridyl ethers.

  本发明涉及一系列取代吡啶化合物，一种利用这些化合物在哺乳动物中选择性控制神经递质释放的方法，以及含有这些化合物的药物组合物。首选的化合物是3′-(5′-和/或6′-取代)吡啶醚。
• Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5)
  作者：Rachel L. Palte、Sebastian E. Schneider、Michael D. Altman、Robert P. Hayes、Shuhei Kawamura、Brian M. Lacey、My Sam Mansueto、Michael Reutershan、Phieng Siliphaivanh、Christopher Sondey、Haiyan Xu、Zangwei Xu、Yingchun Ye、Michelle R. Machacek

  DOI：10.1021/acsmedchemlett.9b00525

  日期：2020.9.10

  Protein arginine methyltransferase 5 (PRMT5) belongs to a family of enzymes that regulate the posttranslational modification of histones and other proteins via methylation of arginine. Methylation of histones is linked to an increase in transcription and regulates a manifold of functions such as signal transduction and transcriptional regulation. PRMT5 has been shown to be upregulated in the tumor environment of several cancer types, and the inhibition of PRMT5 activity was identified as a potential way to reduce tumor growth. Previously, four different modes of PRMT5 inhibition were known-competing (covalently or non-covalently) with the essential cofactor Sadenosyl methionine (SAM), blocking the substrate binding pocket, or blocking both simultaneously. Herein we describe an unprecedented conformation of PRMT5 in which the formation of an allosteric binding pocket abrogates the enzyme's canonical binding site and present the discovery of potent small molecule allosteric PRMT5 inhibitors.
• SUBSTITUTED PYRIDINE COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION
  申请人：ABBOTT LABORATORIES

  公开号：EP1257535A1

  公开（公告）日：2002-11-20
• US6656958B2
  申请人：——

  公开号：US6656958B2

  公开（公告）日：2003-12-02